New · CUSIP 74019P207 · who reports it, how much, and how much it matters to them
14 of the 720 hedge fund managers we track reported shares of Precision Biosciences Inc (Nasdaq: DTIL) on Form 13F for 30 June 2026. Between them they reported USD 51m. The largest position belongs to Bleichroeder, at USD 16m. The manager with the most riding on it is Empery Asset Management, where it is 7.1% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Bleichroeder4 funds on PPLI.com | USD 16m | 2.8% |
| 2 | Octagon Capital Advisors1 fund on PPLI.com | USD 11m | 1.0% |
| 3 | Boothbay Fund Management2 funds on PPLI.com | USD 11m | 0.1% |
| 4 | Empery Asset Management5 funds on PPLI.com | USD 6.1m | 7.1% |
| 5 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 2.2m | 0.1% |
| 6 | Two Sigma Investments35 funds on PPLI.com | USD 1.9m | 0.0% |
| 7 | Squarepoint Ops7 funds on PPLI.com | USD 1.1m | 0.0% |
| 8 | The Quarry1 fund on PPLI.com | USD 770,000 | 0.1% |
| 9 | Renaissance Technologies13 funds on PPLI.com | USD 539,000 | 0.0% |
| 10 | Citadel Advisors32 funds on PPLI.com | USD 539,000 | 0.0% |
| 11 | Graham Capital Management18 funds on PPLI.com | USD 168,000 | 0.0% |
| 12 | Engineers Gate Manager1 fund on PPLI.com | USD 164,000 | 0.0% |
| 13 | POINT72 Asset Management17 funds on PPLI.com | USD 111,000 | 0.0% |
| 14 | Verdad Advisers6 funds on PPLI.com | USD 106,000 | 0.1% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Empery Asset Management | USD 6.1m | 7.1% |
| 2 | Bleichroeder | USD 16m | 2.8% |
| 3 | Octagon Capital Advisors | USD 11m | 1.0% |
| 4 | Boothbay Fund Management | USD 11m | 0.1% |
| 5 | Verdad Advisers | USD 106,000 | 0.1% |
| 6 | Arrowmark Colorado Holdings | USD 2.2m | 0.1% |
| 7 | The Quarry | USD 770,000 | 0.1% |
| 8 | Graham Capital Management | USD 168,000 | 0.0% |
| 9 | Engineers Gate Manager | USD 164,000 | 0.0% |
| 10 | Two Sigma Investments | USD 1.9m | 0.0% |
Precision Biosciences Inc trades under the symbol DTIL on the Nasdaq. Its CUSIP, the code used on Form 13F, is 74019P207.
14 of the 720 hedge fund managers PPLI.com tracks reported Precision Biosciences Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Bleichroeder (USD 16m), Octagon Capital Advisors (USD 11m), Boothbay Fund Management (USD 11m), Empery Asset Management (USD 6.1m) and Arrowmark Colorado Holdings (USD 2.2m).
14 managers in our coverage reported it, and between them they run 166 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Empery Asset Management, where the position was 7.1% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Precision Biosciences Inc or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.